TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday, January 20th.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other research analysts also recently issued reports about the stock. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 12th. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Wednesday, December 20th. Deutsche Bank set a $9.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, December 20th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target on shares of TherapeuticsMD in a report on Wednesday, November 29th. Finally, Oppenheimer set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.50.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $5.48 on Friday. The firm has a market cap of $1,190.00, a P/E ratio of -14.05 and a beta of 0.99. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30.
In related news, Director Tommy G. Thompson purchased 5,000 shares of the stock in a transaction dated Friday, December 8th. The stock was purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 23.92% of the stock is owned by insiders.
A number of large investors have recently modified their holdings of TXMD. Schwab Charles Investment Management Inc. raised its position in TherapeuticsMD by 10.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares during the last quarter. Rhumbline Advisers raised its position in TherapeuticsMD by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after buying an additional 6,232 shares during the last quarter. Legal & General Group Plc raised its position in TherapeuticsMD by 6.5% in the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after buying an additional 3,441 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of TherapeuticsMD by 10.8% during the 2nd quarter. Alliancebernstein L.P. now owns 254,240 shares of the company’s stock valued at $1,340,000 after purchasing an additional 24,700 shares during the last quarter. 72.65% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/therapeuticsmd-txmd-upgraded-to-hold-by-zacks-investment-research.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.